Kris on the Success of Durvalumab as a Major Advancement in NSCLC

In an interview with Targeted Oncology, Kris, a medical oncologist and the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, discussed how the approval of durvalumab has changed the treatment landscape of NSCLC.

Read full article (External website)

1 reply

Trackbacks & Pingbacks

  1. […] fbq('init', '1900017183557956'); fbq('track', 'PageView'); Original article (External […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply